Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Pasireotide LAR in Advanced Uveal Melanoma
NCT01252251Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2010
- Primary completion
- Jun 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR and everolimus in Uveal melanoma (UM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Number of Participants With Complete Response at 16 weeks, Number of Participants With Partial Response at 16 weeks and 1 more. Started Nov 2010; status: completed.
02
Drugs
pasireotide LAReverolimus
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT01252251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01252251.